

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/12, C07K 14/705, A61K 48/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/11268</b> <b>(43) International Publication Date:</b> 18 April 1996 (18.04.96)
<b>(21) International Application Number:</b> PCT/US95/11595 <b>(22) International Filing Date:</b> 14 September 1995 (14.09.95)  <b>(30) Priority Data:</b> 08/319,183                      6 October 1994 (06.10.94)                      US  <b>(71) Applicant:</b> WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).  <b>(72) Inventors:</b> BISGAIER, Charles, Larry; 3605 Tanglewood Drive, Ann Arbor, MI 48105 (US). CORNICELLI, Joseph, Anthony; 2878 Eisenhower Parkway, Ann Arbor, MI 48108 (US). WOELE, Sabine; 435 Village Green Boulevard #208, Ann Arbor, MI 48105 (US).  <b>(74) Agents:</b> RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		<b>(81) Designated States:</b> CA, EE, JP, LT, LV, MX, SI, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHOD OF USING A SCAVENGER RECEPTOR IN THE TREATMENT OF ATHEROSCLEROSIS  <b>(57) Abstract</b>  <p>A method for introducing a scavenger receptor gene into a mammal to make said mammal resistant to atherosclerosis; an artificial scavenger receptor minigene or partial minigene as well as the ectopic expression of a scavenger receptor in the liver of a mammal for the reduction of apo B containing lipoproteins, elevation of high-density lipoprotein cholesterol, and prevention of atherosclerosis; and a method of treating atherosclerosis, hyperbetalipoproteinemia (i.e., high-levels of apolipoprotein (apo) B containing lipoproteins), hypercholesterolemia, hypertriglyceridemia; hypoalphalipoproteinemia (i.e., low levels of high-density lipoprotein), vascular complications of diabetes, transplant, atherectomy, and angioplastic restenosis in a patient with a therapeutically effective amount of a scavenger receptor gene alone or combined with a ACAT inhibitor, a HMG-CoA reductase inhibitor, a bile acid sequestrant, or lipid regulator, and pharmaceutical delivery methods which include these agents.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHOD OF USING A SCAVENGER RECEPTOR IN THE TREATMENT  
OF ATHEROSCLEROSIS

5

BACKGROUND OF THE INVENTION

The present invention relates to a medical method of treatment. In particular, the present invention concerns the use of a scavenger receptor gene (SR) to make a mammal resistant to atherosclerosis, to methods for their production, to pharmaceutical delivery methods which include these genes, and to pharmaceutical methods of treatment. In particular, the novel SR gene is useful in treating hyperbetalipoproteinemia (i.e., high levels of apolipoprotein (apo) B containing lipoproteins), hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia (i.e., low levels of high-density lipoprotein cholesterol), vascular complications of diabetes, transplant, atherectomy, and angioplastic restenosis. More particularly, the novel SR gene alone or combined with another agent for the treatment of atherosclerosis such as, for example, an ACAT inhibitor, a HMG-CoA reductase inhibitor, a lipid regulator, a bile acid sequestrant, and the like is useful in the treatment of atherosclerosis.

The macrophage is thought to play a pivotal role in the pathogenesis of atherosclerosis (Brown M.S., Goldstein J.L., Krieger M., Ho Y.K., Anderson R.G.W., J. Cell Biol., 82:597-613 (1979); Goldstein J.L., Ho Y.K., Basu S.K., Brown M.S., Proc. Natl. Acad. Sci. USA, 76:333-337 (1979); Brown M.S., Goldstein J.L., Ann. Review Biochem., 52:223-261 (1983); Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L., N. Engl. J. Med., 320:915-924 (1989); Carew T.E., Am. J. Cardiol.,

-2-

- 64:18G-22G (1989); Brown M.S., Goldstein J.L.,  
Nature, 343:508-509 (1990); Kurihara Y.A.,  
Matsumoto A., Itakura H., Kodama T., Current Opinion  
5 in Lipidology, 2:295-300 (1991); Krieger M., TIBS,  
17:141-146 (1992)). SRs are present on macrophages  
and mediate binding and internalization of a broad  
variety of ligands including modified apo B  
containing lipoproteins (Brown M.S., Goldstein J.L.,  
Krieger M., Ho Y.K., Anderson R.G.W., *supra.*, 1979;  
10 Goldstein J.L., Ho Y.K., Basu S.K., Brown M.S.,  
*supra.*, 1979; Brown M.S., Goldstein J.L., *supra.*,  
1983; Steinberg D., Parthasarathy S., Carew T.E.,  
Khoo J.C., Witztum J.L., *supra.*, 1989; Carew T.E.,  
*supra.*, 1989; Brown M.S., Goldstein J.L., *supra.*,  
15 1990; Kurihara Y.A., Matsumoto A., Itakura H.,  
Kodama T., *supra.*, 1991; Krieger M., *supra.*, 1992;  
Fogelman A.M., Shechter I., Seager J., Hokom M.,  
Child J.S., Edwards P.A., Proc. Natl. Acad. Sci. USA,  
77:2214-2218 (1980); Haberland M.E., Fogelman A.M.,  
20 Proc. Natl. Acad. Sci. USA, 82:2693-2697 (1985);  
Horiuchi S., Murakami M., Takata K., Morino Y.,  
J. Biol. Chem., 261:4962-4966 (1986); Dresel H.A.,  
Friedrich E., Via D.P., Sinn H., Ziegler R.,  
Schettler G., EMBO Journal, 6:319-326 (1987);  
25 Quinn M.T., Parthasarathy S., Fong L.G.,  
Steinberg D., Proc. Natl. Acad. Sci. USA, 84:2995-  
2998 (1987); Takata K., Horiuchi S., Araki N.,  
Shiga M., Saitoh M., Morino Y., J. Biol. Chem.,  
263:14819-14825 (1988); Wright T.L., Roll F.J.,  
30 Jones A.L., Weisiger R.A., Gastroenterology,  
94:442-452 (1988); Takata K., Horiuchi S., Morino Y.,  
Biochim. Biophys. Acta., 984:273-280 (1989);  
Eskild W., Kindberg G.M., Smedsrød B., Blomhoff R.,  
Norum K.R., Berg T., Biochem. J., 258:511-520 (1989);  
35 Steinbrecher U.P., Loughheed M., Kwan W.-C., Dirks M.,  
J. Biol. Chem., 264:15216-15223 (1989); Hampton R.Y.,

-3-

Golenbock D.T., Penman M., Krieger M., Raetz C.R.H.,  
Nature, 352:342-344 (1991); Stehle G.,  
Friedrich E.A., Sinn H., et al., J. Clin. Invest.,  
90:2110-2116 (1992); Tokuda H., Masuda S.,  
5 Takakura Y., Sezaki H., Hashida M., Biochem. Biophys.  
Res. Commun., 196:18-24 (1993); de Vries H.E.,  
Kuiper J., de Boer A.G., van Berkel T.J.C.,  
Breimer D.D., J. Neurochem., 61:1813-1821 (1993);  
Pearson A.M., Rich A., Krieger M., J. Biol. Chem.,  
10 268:3546-3554 (1993); Zhang H., Yang Y.,  
Steinbrecher U.P., J. Biol. Chem., 268:5535-5542  
(1993); Dunne D.W., Resnick D., Greenberg J.,  
Krieger M., Joiner K.A., Proc. Natl. Acad. Sci. USA,  
91:1863-1867 (1994); Freeman M.W., Current Opinion in  
15 Lipidology, 5:143-148 (1994)). The SR may also be  
present on smooth muscle and endothelial cells under  
specific circumstances (Bickel P.E., Freeman M.W.,  
J. Clin. Invest., 90:1450-1457 (1992)). Unlike the  
low-density lipoprotein (LDL) receptor, the SR lacks  
20 negative feedback regulation by cholesterol allowing  
the sustained uptake of modified lipoprotein and  
transformation of macrophages into foam cells  
(Brown M.S., Goldstein J.L., Krieger M., Ho Y.K.,  
Anderson R.G.W., supra., 1979; Goldstein J.L.,  
25 Ho Y.K., Basu S.K., Brown M.S., supra., 1979;  
Brown M.S., Goldstein J.L., supra., 1983). The  
macrophage derived foam cell is characteristic of  
early atherosclerotic lesions in a variety of species  
including humans; its accelerated formation can be  
30 mimicked in a variety of animal models fed  
cholesterol-enriched diets (Mahley R.W., Athero.  
Rev., 5:1-34 (1979); Clarkson T.B., Shively C.A.,  
Weingand K.W., Comp. Anim. Nutr., 6:56-82 (1988)).

Two forms of bovine SRs, Type I and II, have  
35 been cloned from bovine lung libraries (Kodama T.,  
Freeman M., Rohrer L., Zabrecky J., Matsudaira P.,

-4-

Kreiger M., Nature, 343:531-535 (1990); Rohrer L., Freeman M., Kodama T., Penman M., Kreiger M., Nature, 343:570-572 (1990)). These trimeric structurally similar receptors are derived from alternate splicing of a single gene product resulting in SR that contain (Type I) or lack (Type II) the carboxyl terminal cysteine-rich domain (Freeman M., Ashkenas J., Rees D.J.G., et al., Proc. Natl. Acad. Sci. USA, 87:8810-8814 (1990)). Although the cysteine-rich domain (i.e., Type I, Domain VI) is highly conserved between species, its functional significance is not known. Mutagenesis studies of Acton, et al. (Acton S., Resnick D., Freeman M., Ekkel Y., Ashkenas J., Krieger M., J. Biol. Chem., 268:3530-3537 (1993)), suggest the collagenous domains (Domain V) present in both Type I and II SR contain the sequence necessary for recognition of polyanionic ligands. Structural studies of Penman, et al. (Penman M., Lux A., Freedman N.J., et al., J. Biol. Chem., 266:23985-23993 (1991)), have suggested that the assembly of SR into trimers involves the noncovalent association of a spacer domain (i.e., Domain III) disulfide linked dimer with a monomer. The trimeric SR structure, however, does not appear to be requisite for functional binding since monomers are fully capable of binding ligands (Via D.P., Kempner E.S., Pons L., et al., Proc. Natl. Acad. Sci. USA, 89:6780-6784 (1992)).

Although overwhelming circumstantial evidence suggest modified LDL exists in vivo (Carew T.E., supra., 1989), their presence has been viewed with skepticism since these particles have not been isolated from plasma. It is likely their compartmentalized formation in the subendothelium and rapid uptake by resident macrophages prevent any accumulation in plasma. However, in vitro and

-5-

in vivo, macrophage SR avidly bind, internalize, and degrade chemically modified LDL. Although smooth muscle cell and macrophage SR expression in the artery wall may play a role in lesion formation, their presence in liver may portend a protective role (Brown M.S., Goldstein J.L., supra., 1990). Indeed, nonparenchymal liver cells, including Kupffer and endothelial cells are capable of binding and degradation of acetylated and oxidized LDL (Dresel H.A., Friedrich E., Via D.P., Sinn H., Ziegler R., Schettler G., supra., 1987; van Berkel T.J.C., Nagelkerke J.F., Kruijt J.K., FEBS Letters, 132:61-66 (1981); Dresel H.A., Friedrich E., Via D.P., Schettler G., Sinn H., EMBO Journal, 4:1157-1162 (1985); de Rijke Y.B., van Berkel T.J.C., J. Biol. Chem., 269:824-827 (1994)). Furthermore, intravenously infused acetylated LDL accumulates primarily in hepatic sinusoidal and endothelial cells, and to a lesser extent in Kupffer cells (Dresel H.A., Friedrich E., Via D.P., Sinn H., Ziegler R., Schettler G., supra., 1987; Dresel H.A., Friedrich E., Via D.P., Schettler G., Sinn H., supra., 1985; Nagelkerke J.F., Barto K.P., van Berkel T.J.C., J. Biol. Chem., 258:12221-12227 (1983); Pitas R.E., Boyles J., Mahley R.W., Montgomery B.D., J. Cell Biol., 100:103-117 (1985); Horiuchi S., Takata K., Maeda H., Morino Y., J. Biol. Chem., 259:53-56 (1985); van Berkel T.J.C., de Rijke Y.B., Kruijt J.K., J. Biol. Chem., 266:2282-2289 (1991)). Studies utilizing oxidized LDL have instead primarily demonstrated ligand accumulation in Kupffer, and to a lesser extent in endothelial cells (Esbach S., Pieters M.N., Van der Boom J., et al., Hepatology, 18:537-545 (1993)). Acetylated LDL uptake by hepatic parenchyma occurs at a near negligible rate

-6-

(Nagelkerke J.F., Barto K.P., van Berkel T.J.C., supra., 1983). Overall, these studies suggest the liver nonparenchymal cells have the capacity to remove potentially atherogenic lipoproteins.

5        Thus, an object of the present invention is the ectopic expression of a SR in mammalian cells, and in particular hepatic cells that do not normally express it. It has surprisingly and unexpectedly been found that expression of the SR in liver cells caused a  
10       drop in apo B containing lipoprotein and an elevation in high-density lipoprotein (HDL) and a favorable change in the ratio of apo B containing lipoprotein cholesterol to HDL cholesterol. Further, it has  
15       unexpectedly been found that liver, containing these ecotopically expressed SRs, is protected from cholesterol accumulation and does not store excess lipids.

20

## SUMMARY OF THE INVENTION

Accordingly, the present invention is directed to a method for introducing a SR gene into the liver of a mammal to make said mammal resistant to  
25       atherosclerosis, comprising introducing the DNA into a mammal by a process of delivery selected from the group consisting of:

- (a) use of calcium phosphate coprecipitation;
- (b) in a complex of cationic liposomes;
- 30       (c) electroporation;
- (d) receptor-mediated endocytosis;
- (e) naked DNA;
- (f) transduction by a viral vector;
- (g) particle-mediated gene transfer; and
- 35       (h) synthetic peptides.



-7-

In a preferred embodiment of the first aspect of the invention, the mammal is a human.

5 In a second aspect, the present invention is directed to a method for introducing a SR gene into a mammal to make said mammal resistant to atherosclerosis comprising inserting said SR gene into a vector and expressing the SR in the liver of said mammal.

10 In a preferred embodiment of the second aspect of the invention, the mammal is a human.

In a third aspect, the present invention is directed to an artificial SR minigene or partial minigene comprising:

- 15 (a) a liver specific promoter or wherein the liver specific promoter is absent;
- (b) a 5' untranslated region or wherein the 5' untranslated region is absent;
- (c) a coding sequence;
- (d) a 3' untranslated region or wherein the 20 3' untranslated region is absent; and
- (e) a polyadenylation signal or wherein the polyadenylation signal is absent.

25 In a preferred embodiment of the third aspect of the invention the 5' untranslated region is selected from the group consisting of: a 5' untranslated region containing natural (heterologous or homologous) nucleotides; a 5' untranslated region containing synthetic nucleotides; and a 5' 30 untranslated region containing a combination of natural (heterologous or homologous) and synthetic nucleotides.

35 In a more preferred embodiment of the third aspect of the invention the 5' untranslated region is selected from a group consisting of: a 5' untranslated region between the promoter and

-8-

translation initiation site(s) of the SR coding region; and a 5' untranslated region excluding a 5' untranslated region between the promoter and translation initiation site(s) of the SR coding region:

In a most preferred embodiment of the third aspect of the invention the 5' untranslated region between the promoter and the SR coding region is 5 bp of the 5' untranslated region of the SR.

In a preferred embodiment of the third aspect of the invention the 3' untranslated region is selected from the group consisting of: a region between the 3' end of the SR coding sequence and the 3' end of a sequence containing a poly-A tail consisting of natural (heterologous or homologous) nucleotides; a region between the 3' end of the SR coding sequence and the 3' end of a sequence containing a poly-A tail consisting of synthetic nucleotides; and a region between the 3' end of the SR coding sequence and the 3' end of a sequence containing a poly-A tail consisting of a combination of natural (heterologous or homologous) and synthetic nucleotides.

In a more preferred embodiment of the third aspect of the invention the 3' untranslated region is selected from the group consisting of: a region between the 3' end of the SR coding sequence and a 5' end of a sequence containing a poly-A tail; and exclusion of a region between the 3' end of the SR coding sequence and a 5' end of a sequence containing a poly-A tail.

In a most preferred embodiment of the third aspect of the invention the 3' untranslated region is truncated at the specific restriction site using the enzyme Asp700 or any other isochizomer of Asp700.

In a preferred embodiment of the third aspect of the invention the polyadenylation signal is selected

-9-

from the group consisting of: a polyadenylation signal containing natural (heterologous or homologous) nucleotides; a polyadenylation signal containing synthetic nucleotides; and a  
5 polyadenylation signal containing a combination of natural (heterologous or homologous) and synthetic nucleotides.

In a more preferred embodiment of the third aspect of the invention, the polyadenylation signal  
10 is the human growth hormone sequence spanning the polyadenylation signal.

In a most preferred embodiment of the third aspect of the invention the polyadenylation signal is  
15 650 bp sequence of the human growth hormone sequence spanning the polyadenylation signal.

In a preferred embodiment of the third aspect of the invention the liver specific promoter is the mouse transferrin promoter.

In a more preferred embodiment of the third aspect of the invention the coding sequence is  
20 selected from the group consisting of: the complete coding sequence; a truncated form of the coding sequence; and fragments of the complete coding sequence including insertions, deletions, and  
25 repetitions.

In a fourth aspect, the present invention is directed to the ectopic expression of a SR in the liver of a mammal for the reduction of apo B containing lipoproteins, elevation of high-density  
30 lipoprotein cholesterol, and prevention of atherosclerosis.

In a preferred embodiment of the fourth aspect of the invention, the mammal is a human.

In a more preferred embodiment of the fourth aspect of the invention the expression is transient  
35 expression in the liver.

-10-

In a most preferred embodiment of the fourth aspect of the invention the expression is stable expression in the liver.

5 In a fifth aspect, the present invention is directed to a method of treating atherosclerosis; hyperbetalipoproteinemia; hypercholesterolemia; hypertriglyceridemia; hypoalphalipoproteinemia; vascular complications of diabetes; transplant, atherectomy, and angioplastic restenosis  
10 (Groves P.H., Lewis M.J., Cheadle H.A., Penny W.J., Circulation, 87:590-597 (1993); More R.S., Rutty G., Underwood M.J., Gershlick A.H., J. Pathol., 172:287-292 (1994)) in a patient comprising administering to the liver of said patient a therapeutically effective  
15 amount of a SR gene.

In a sixth aspect, the present invention is directed to a method of treating atherosclerosis; hyperbetalipoproteinemia; hypercholesterolemia; hypertriglyceridemia; hypoalphalipoproteinemia;  
20 vascular complications of diabetes; transplant, atherectomy, and angioplastic restenosis in a patient comprising administering to the liver of said patient a therapeutically effective amount of a SR gene in combination with one or more agents selected from the  
25 group consisting of:  
(a) ACAT inhibitor;  
(b) HMG CoA reductase inhibitor;  
(c) lipid regulator; and  
(d) bile acid sequestrant.

30

In a seventh aspect, the present invention is directed to a pharmaceutical delivery method adapted for hepatic administration to a patient in an effective amount of an agent for treating  
35 atherosclerosis; hyperbetalipoproteinemia; hypercholesterolemia; hypertriglyceridemia;

-11-

hypoalphalipoproteinemia; vascular complications of diabetes; transplant, atherectomy, and angioplastic restenosis comprising a SR gene and a suitable viral or nonviral delivery system.

5 In a preferred embodiment of the seventh aspect of the invention, the pharmaceutical delivery method is adapted for ex vivo or in vivo delivery.

10 In a most preferred embodiment of the seventh aspect of the invention, the pharmaceutical delivery method is directed to therapeutic or prophylactic administration.

#### BRIEF DESCRIPTION OF THE DRAWINGS

15

The invention is further described by the following nonlimiting examples which refer to the accompanying Figures 1 to 10, short particulars of which are given below.

20

#### Figure 1

The 5.2 kb construct of the bovine SR Type I minigene. A full length bovine SR cDNA (black bar) was truncated in the 3' untranslated region at the single restriction site Asp700. The ~1.6 kb fragment was then ligated to a 0.65 kb containing the poly A signal sequence of the human growth hormone gene (white bar) using the Sma I and Asp700 fusion site. At the 5' end, a 3 kb DNA fragment of the mouse transferrin promoter (stippled box) was attached using Bam HI. The minigene was inserted into a pGem 11Zf (-) using Eco RI at the 5' end and Not I at the 3' end. The region between the Bam HI site at the 3' end of the mouse transferrin promoter and the first ATG codon of the SR cDNA contained 5 base pairs (5' - gaagt-3') of the untranslated region of the bovine SR

25

30

35

-12-

allowing the first ATG to be in the optimal context for translation initiation (Kozak M., Cell, 47:481-483 (1986); Kozak M., J. Cell Biol., 108:229-241 (1989)).

5

### Figure 2

(A) Reverse transcriptase-polymerase chain reaction of hepatic RNA from a control and a TgSR<sup>+/-</sup> mouse shows the presence of a 1 kb amplified region of bovine SR mRNA. Reference DNA size standards are shown (1 kb marker). (B) Northern blot analysis of a bovine SR Type I expressing mouse. For each tissue sample 10 µg of total RNA was electrophoretically fractionated on a formaldehyde - 1% agarose gel, transferred onto Zetaprobe membranes, and then hybridized to a bovine SR Type I specific cDNA probe as indicated in Figure 1. The probe did not hybridize to RNA isolated from control mouse tissues under the same conditions (not shown). The blot was washed and exposed to X-Omat AR film at -80°C overnight.

10  
15  
20

### Figure 3

Western blot analysis of a TgSR<sup>+/-</sup> and control mouse liver membrane preparation. Nonreduced membrane protein (22.5 µg/lane) was loaded onto 7.5% SDS polyacrylamide gel and transferred to nitrocellulose membranes and the presence of bovine SR were determined as described in Example 5. Monomeric plus possibly monomeric precursors, dimeric, and trimeric forms of the bovine SR are apparent.

25  
30

-13-

Figure 4

Hepatic fluorescent histochemistry following DiI-acetylated human LDL infusion in control and TgSR+/- mice. Mice were intravenously infused with DiI-acetylated human LDL and sacrificed after 10 minutes. Liver pieces were embedded in O.C.T., 3 to 5  $\mu$ M slices prepared and viewed by fluorescent microscopy using a rhodamine filter set. Top panel shows a control mouse hepatic section demonstrating nonparenchymal cell to DiI uptake evidenced by fluorescence being confined to elongated cells surrounding sinusoids. The bottom panel shows a section from a TgSR+/- mouse. In addition to DiI uptake by nonparenchymal cells, extensive dye uptake occurred in polyhedral-shaped parenchymal cells (donut-shaped cells) as evidenced by the perinuclear staining. Sinusoidal cells, arrows; parenchymal cell nucleus, N.

Figure 5

Clearance of  $^{125}$ I-acetylated-hLDL in control and TgSR+/- mice. Five TgSR+/- (●) and five control (○) mice were tail vein injected with  $^{125}$ I-ac-hLDL. Blood samples were collected periodically up to 8 minutes to determine plasma radioactivity clearance. To control for nonscavenger receptor mediated  $^{125}$ I-ac-hLDL clearance, three TgSR+/- (■) and three control (□) mice were coinjected with 0.1 mL of  $^{125}$ I-ac-hLDL preparation plus 0.1 mL Fucoidan. Radioactivity data are expressed as percent of the first 20-second time point. Each data point represents data averaged from five ( $^{125}$ I-ac-hLDL alone) or three mice ( $^{125}$ I-ac-hLDL plus Fucoidan).

-14-

Figure 6

Lipoprotein cholesterol analysis of plasma from nontransgenic control (FVB  $\times$  C57BL/6J), TgSR+/-, and TgSR+/+ mice maintained on chow or fed the HFHC diet for up to 3 weeks. High performance gel-filtration chromatographic lipoprotein profile analysis of 10  $\mu$ L plasma from these mice was determined weekly as described in Example 11. A blood sample from TgSR+/+ Mouse 242 on chow was not obtained, and control Mouse 148 died from anesthesia overdose at 2 weeks. Although not shown on the figure the peak height (Y-axis) = OD 490, and is the same scale for each of the 12 groups shown.

15 Figure 7

Plasma cholesterol in apo B containing lipoproteins (Top Panel), HDL (Middle Panel), and the apo B containing lipoprotein to HDL cholesterol ratio (lower panel) in nontransgenic control (●, n = 4 or 5), TgSR+/- (▲, n = 5), and TgSR+/+ (■, n = 3 or 4) mice maintained on chow or fed the HFHC diet for up to 3 weeks. Total plasma cholesterol (Table I) and lipoprotein profiles from data shown in Figure 6 were used for the determinations. Data points represent the mean  $\pm$  SEM.

Figure 8

Hepatic lipid analysis in TgSR+/- mice. In the top panel, typical livers from control and TgSR+/- mice maintained on chow diets showed no evidence of the fatty accumulation. Livers from control mice fed the HFHC diet were always white indicative of a fatty liver, while livers from TgSR+/- mice fed the HFHC diet appeared only slightly discolored. The lower panel shows hepatic lipid analysis from the



-15-

four control and five TgSR+/- mice after 3 weeks on the high-fat, high- cholesterol diet (i.e., from animals studied in Table I, Figure 6 and 7). Data represent the mean  $\pm$  SEM. Significance difference in mean was determined by a Student's t-test for unpaired data.

#### Figure 9

Total fecal bile acids were determined weekly in five control ( $\square$ ) and five TgSR+/- ( $\blacksquare$ ) mice fed chow, and then the HFHC diet for 3 weeks as described in Example 13. Data represent the mean  $\pm$  SEM.

#### Figure 10

Two control and two heterozygous SR transgenic mice were fed the high-fat, high-cholesterol diet for 3 weeks. Hepatic total RNA (10  $\mu$ g/lane) were run on duplicate gels, blotted and probed for mouse 7 $\alpha$ -hydroxylase or mouse actin as described in Example 3. The 7 $\alpha$ -hydroxylase to actin ratio was elevated 2-fold in the SR transgenic mice. Data represent the average of 2 mice per group.

### DETAILED DESCRIPTION OF THE INVENTION

The term "transient expression" means the expression of a transfected gene that is temporary, usually lasting only a few days to a few weeks.

The term "stable expression" means the expression of a transfected gene where the expression is sustained.

The term "mammal" includes humans.

The term "liver specific promoter" means a promoter constructed of either homologous or

-16-

heterologous promoter elements either naturally occurring or artificially, including synthetically created.

5 The term "partial minigene" means a minigene lacking one or more elements outside the coding sequence such as, for example, a promoter, a 5' untranslated region, a 3' untranslated region, a polyadenylation signal, and the like.

10 In order to directly determine whether or not hepatic SRs have a protective anti-atherosclerotic role, transgenic mice overexpressing hepatic bovine SR Type I were created in the genetic background of the FVB mouse crossed to the atherosclerosis susceptible C57BL/J6 mouse. Both heterozygous  
15 (TgSR+/-) and homozygous (TgSR+/+) mice were created. Uptake of modified lipoproteins was greatly enhanced in the liver of these animals. Furthermore, when fed cholesterol-enriched diets, these mice present with marked reductions in apo B-containing lipoproteins  
20 and hepatic cholesteryl esters, and increased hepatic 7 $\alpha$ -hydroxylase mRNA levels and total fecal bile acids. These data directly demonstrate a potential in vivo anti-atherosclerotic role of hepatic scavenger receptors.

25

#### Creation of SR Transgenic Mice

To create mice with hepatic expression of the bovine SR Type I, a SR minigene containing the mouse transferrin promotor was constructed (Figure 1).  
30 Based on the work of Kozak, et al. (Kozak M., supra., 1986; Kozak M., supra., 1989), 5 bp of the untranslated region of the bSR cDNA sequence (Idzerda R.L., Behringer R.R., Theisen M., Huggenvik J.I., McKnight G.S., Brinster R.L., supra.,  
35 1989) was incorporated into the construct since inclusion of this element should facilitate correct

-17-

initiation and highly efficient translation of the SR. In our experiments this concept was not examined rigorously in that we did not construct nor test a minigene lacking these 5 bp. The SR minigene was  
5 injected into hybrid fertilized eggs obtained from a C57BL/6J female crossed to a FVB male. PCR and Southern blotting indicated three potential transgenic mice were created (data not shown). These mice were breed to C57BL/6J  $\times$  FVB; offspring from  
10 these crosses indicated that out of the three potential founders, two were chimerics and one had transgene integration into the germline. Southern blot results suggested approximately 30 copies of the transgene were present per cell. In some studies,  
15 TgSR+/- were crossed to generate homozygous mice (TgSR+/+).

#### Expression of the Bovine SR in Transgenic Mice

Tissue-specific expression of bovine SR mRNA was  
20 examined by RT-PCR and Northern blot analysis of total RNA isolated from tissue of TgSR+/- and nontransgenic controls (C57BL/6J  $\times$  FVB). By RT-PCR a 1kb cDNA fragment was amplified in a TgSR+/- but not in a control mice (Figure 2), demonstrating the  
25 presence of bovine SR mRNA in the TgSR+/- mouse liver. Bovine SR mRNA was predominantly expressed in liver with a much smaller amount found in kidney. A minute amount of bovine SR expression was also observed in brain (Figure 2). We estimate, hepatic  
30 mRNA levels of the bovine SR to be approximately 20- to 30-fold higher than the endogenous mouse SR (data not shown).

Detergent solubilized nonreduced liver membrane preparations from the TgSR+/- mice revealed the  
35 presence of monomeric plus possibly monomeric precursors (up to ~80 kDa), dimeric (~160 kDa), and

-18-

trimeric (~240 kDa) forms of the bovine SR by Western blotting (Figure 3).

#### Hepatic Parenchymal and Nonparenchymal Expression of the Bovine SR

5           Histological examination of liver sections following intravenous infusion of fluorescent DiI-acetylated human LDL in control and TgSR+/- mice indicates the presence of the fluorescence probe in  
10 both nonparenchymal Kupffer and sinusoidal cells (Figure 4). However, unlike nontransgenic mouse, TgSR+/- mouse liver parenchymal cells were fluorescent suggesting these cells expressed the transgene (Figure 4).

15

#### Fractional Catabolism of $^{125}\text{I}$ -Acetylated LDL in SR Transgenic Mice

          The fractional catabolism of  $^{125}\text{I}$ -ac-hLDL was determined in five TgSR+/- and five nontransgenic  
20 littermates. Mice were tail vein injected with the probe and 10  $\mu\text{L}$  sinus orbital bleeds were periodically taken up to 8 minutes. The  $t_{1/2}$  for  $^{125}\text{I}$ -ac-hLDL clearance in the TgSR+/- was 2.5 times faster (75 seconds) than in control mice (186  
25 seconds) (Figure 5). In three TgSR+/- and three nontransgenic littermates simultaneously injected with both Fucoidan and  $^{125}\text{I}$ -ac-hLDL, the SR mediated clearance of the probe was blocked (Figure 5).

30

#### Plasma Lipids and Lipoprotein Profiles

          Weekly plasma triglycerides and total cholesterol from control, TgSR+/-, and TgSR+/+ mice initially on a chow diet then maintained on a HFHC  
diets for 3 weeks are shown in Table I. In all mice  
35 and under all dietary conditions plasma triglycerides were similar (Table I) on chow, basal cholesterol

-19-

levels were similar in control and transgenic mice. When fed the high-fat, high-cholesterol diet, total plasma cholesterol rose in all mice. However, at Week 3, total plasma cholesterol in the TgSR<sup>+/-</sup> and TgSR<sup>+/+</sup> mice increased to only 59% and 83%, respectively, of that observed in the control mice. High performance gel-filtration chromatographic lipoprotein profile analysis of plasma from these mice (Figure 6) was utilized to determine the distribution of cholesterol between lipoproteins (Figure 7). On the chow diet lipoprotein cholesterol profiles were similar in control and SR transgenic mice; HDL carried the majority of cholesterol under these conditions (Figures 6 and 7). When fed the HFHC diet, cholesterol predominantly rose in apo B containing lipoproteins relative to HDL in control mice (Figures 6 and 7). In both TgSR<sup>+/-</sup> and TgSR<sup>+/+</sup> mice, apo B containing lipoproteins, rose to only half the amount observed in the control mice (Figures 6 and 7). In the TgSR<sup>+/-</sup> mice, HDL rose more rapidly than the controls, however, after 3 weeks on the HFHC diet HDL cholesterol levels converged (Figure 7). In contrast, in the TgSR<sup>+/+</sup> mice fed the HFHC diet, HDL cholesterol continued to rise and the level was significantly greater than control mice levels at 3 weeks (Figures 6 and 7). These marked differences in lipoprotein profiles can be appreciated as the ratio of apo B-containing lipoprotein cholesterol to that of HDL cholesterol (Figure 7). Thus, in the TgSR<sup>+/-</sup> and TgSR<sup>+/+</sup> mice this ratio rose 2.8-fold with the HFHC diet, while this ratio rose to 6.6-fold in the control mice.

TABLE I  
(Page 1 of 2)

Diet <sup>a,b,c</sup>	Genotype	N	Cholesterol (mg/dL)			Cholesterol Ratio VLDL+IDL+LDL/HDL	Triglyceride (mg/dL)
			Total	VLDL+IDL+LDL	HDL		
Chow Diet	Control	5	60 ± 7	15 ± 3	45 ± 4	0.326 ± 0.031	49 ± 3
	TgSR+/-	5	59 ± 6	14 ± 2	45 ± 5	0.318 ± 0.021	51 ± 10
	TgSR+/+	3	78 ± 7	21 ± 2	56 ± 5	0.383 ± 0.019	56 ± 4

5

Chow Diet Differences <sup>d</sup>							
Control vs TgSR+/-			NS	NS	NS	NS	NS
Control vs TgSR+/+			NS	NS	NS	NS	NS
TgSR+/- vs TgSR+/+			NS	NS	NS	NS	NS

10

Diet <sup>d</sup>	Genotype	N	Cholesterol (mg/dL)			Cholesterol Ratio VLDL+IDL+LDL/HDL	Triglyceride (mg/dL)
			Total	VLDL+IDL+LDL	HDL		
1 Week High-Fat, High-Cholesterol Diet	Control	5	203 ± 37	132 ± 28	71 ± 10	1.800 ± 0.204	52 ± 6
	TgSR+/-	5	174 ± 17	70 ± 10	105 ± 8	0.656 ± 0.041	60 ± 7
	TgSR+/+	4	180 ± 15	77 ± 13	104 ± 7	0.752 ± 0.133	55 ± 6

15

1 Week High-Fat, High-Cholesterol Diet Differences							
Control vs TgSR+/-			NS	0.0045	0.0084	<0.0001	NS
Control vs TgSR+/+			NS	0.0164	0.0155	<0.0001	NS
TgSR+/- vs TgSR+/+			NS	NS	NS	NS	NS

20

<sup>a</sup> Plasma lipids and lipoprotein levels in control, heterozygous transgenic bovine SR (TgSR+/-), and homozygous transgenic bovine SR (TgSR+/+) mice.

<sup>b</sup> Blood samples were obtained following an 8-hour fast from mice on the chow diet; and after 1, 2, and 3 weeks on the high-fat, high-cholesterol diet.

<sup>c</sup> Data represent mean ± SEM.

<sup>d</sup> ANOVA, Fisher's PLSD posthoc analysis, NS = not significant (significance level = 5%), all other as p-values.

25

30

TABLE I  
(Page 2 of 2)

Diet	Genotype	N	Cholesterol (mg/dL)			Cholesterol Ratio VLDL+IDL+LDL/HDL	Triglyceride (mg/dL)
			Total	VLDL+IDL+LDL	HDL		
2 Weeks High-Fat, High-Cholesterol Diet	Control	5	242 ± 26	155 ± 19	88 ± 8	1.768 ± 0.136	39 ± 3
	TgSR+/-	5	190 ± 15	85 ± 8	105 ± 10	0.828 ± 0.098	53 ± 19
	TgSR+/+	4	256 ± 21	99 ± 8	157 ± 16	0.650 ± 0.055	52 ± 2

2 Weeks High-Fat, High-Cholesterol Diet Differences							
Control vs TgSR+/-			NS	0.0018	NS	<0.0001	NS
Control vs TgSR+/+			NS	0.0165	<0.0001	<0.0001	NS
TgSR+/- vs TgSR+/+			0.0319	NS	0.0003	NS	NS

Diet	Genotype	N	Cholesterol (mg/dL)			Cholesterol Ratio VLDL+IDL+LDL/HDL	Triglyceride (mg/dL)
			Total	VLDL+IDL+LDL	HDL		
3 Weeks High-Fat, High-Cholesterol Diet	Control	4	323 ± 35	226 ± 29	96 ± 7	2.340 ± 0.204	38 ± 2
	TgSR+/-	5	192 ± 17	93 ± 14	100 ± 11	1.004 ± 0.240	27 ± 1
	TgSR+/+	4	270 ± 13	132 ± 15	138 ± 11	0.998 ± 0.181	86 ± 27

3 Weeks High-Fat, High-Cholesterol Diet Differences							
Control vs TgSR+/-			<0.0001	<0.0001	NS	<0.0001	NS
Control vs TgSR+/+			NS	0.0002	0.0041	<0.0001	0.0047
TgSR+/- vs TgSR+/+			0.013	0.0842	0.0057	NS	0.0003

-22-

Cholesterol Absorption and Food Intake Studies

Diminished total plasma cholesterol in the transgenic mice could possibly reflect a reduced food intake or an impeded cholesterol absorption. Food intake was, therefore, recorded over a 3-week period for five control and five TgSR+/- on the HFHC diet. Average body weight for each group was 22 g. Weekly food intake was virtually identical between groups; control mice consumed 23.1, 22.9, and 24.3 g/week, while the TgSR+/- mice consumed 21.9, 27.5, and 24.7 g/week, for the first, second, and third week, respectively.

Next, cholesterol absorption was determined in three control and five TgSR+/- mice. Animals were oral gavaged with a  $^3\text{H}$ -cholesterol/ $^{14}\text{C}$ - $\beta$ -sitosterol in sunflower oil, placed on the HFHC diet and feces were collected for 4 days. The  $^3\text{H}/^{14}\text{C}$  ratio in the oral dose and in the neutral lipid fraction extracted from the feces was utilized to estimate the amount of cholesterol absorbed. The percent cholesterol absorption was similar in control ( $56.8 \pm 3.4$ ) and TgSR+/- ( $56.6 \pm 4.4$ ) mice.

Overall these studies suggest the diminished levels of plasma cholesterol observed in the SR transgenic mice is not the result of reduced food intake or cholesterol absorption.

Hepatic Lipids

Gross visual examination of control and TgSR+/- livers from mice maintained on chow diets showed no evidence of fatty accumulations. Livers of control mice fed the HFHC diet showed considerable fat accumulation. In contrast, livers from TgSR+/- mice fed the HFHC diet appeared either normal (not shown) or only slightly discolored (shown) (Figure 8). To determine whether hepatic lipids would accumulate in



-23-

the SR transgenic mice, lipid analysis was performed on the four control and five TgSR+/- mice after 3 weeks on the high-fat, high-cholesterol diet (i.e., from animals studied in Table I, Figures 6 and 7). In the TgSR+/- mice, hepatic cholesteryl esters, triglycerides, and nonesterified cholesterol did not accumulate, but were instead significantly reduced by 59%, 61%, and 36%, respectively (Figure 8). Hepatic phosphatidyl-ethanolamine and phosphatidylcholine levels were similar (Figure 8).

#### Fecal Bile Acids

To determine whether there would be an increase flux of bile acids in the SR transgenic mice, total fecal bile acids were determined weekly in five control and five TgSR+/- mice fed chow 1 week, and the HFHC diet for 3 weeks. On chow, fecal bile acids were similar in control ( $1.51 \pm 0.20$  mg/week) and TgSR+/- ( $1.37 \pm 0.04$  mg/week) mice. On the HFHC diet, fecal bile acids markedly increased 5.4-fold by 1 week ( $8.19 \pm 0.95$  mg/week) and remained constant throughout the study (Week 2,  $8.06 \pm 1.65$  mg/week; Week 3,  $8.49 \pm 0.36$  mg/week). Similarly, the fecal bile acids TgSR+/- mice fed the HFHC diet increased 5.8-fold in the first week ( $7.91 \pm 1.54$ ). In contrast, however, fecal bile acids in the subsequent 2 weeks progressively increased (Week 2,  $9.23 \pm 1.17$  mg/week; Week 3,  $10.83 \pm 0.33$  mg/week) (Figure 9).

#### Hepatic 7 $\alpha$ -Hydroxylase mRNA Levels

To determine if messenger RNA levels for 7 $\alpha$ -hydroxylase (the rate-limiting enzyme for hepatic bile acid synthesis) were elevated to a greater extent in the TgSR+/- mice, total hepatic RNA was extracted from two control and two TgSR+/- mice maintained on the HFHC diet for 3 weeks. Northern blot analysis

-24-

demonstrates 7 $\alpha$ -hydroxylase mRNA levels relative to mouse actin mRNA were elevated 2-fold in the TgSR+/- compared to control mice (Figure 10).

Thus, when the TgSR mice were fed an atherogenic diet, we observed neither a difference in food intake nor in absorption of cholesterol. However, their plasma lipoprotein profiles showed reduced accumulation of apo B containing lipoprotein cholesterol. This effect was quite dramatic. TgSR+/- mice showed almost a 2-fold reduction in the rise of apo B containing lipoproteins after a week on the HFHC diet as compared to the nontransgenic mice. This differential response was consistent throughout the 3-week feeding period. This was in sharp contrast to the normal chow feeding period, in which the nontransgenic and transgenic mice maintained virtually equivalent lipoprotein profiles. Furthermore, when the TgSR+/- mice were on the HFHC diet, a compensatory rise in hepatic cholesterol was not observed; in fact, both hepatic cholesterol and cholesteryl esters were reduced in the transgenic mice. These data suggested an enhanced secretion of biliary cholesterol as bile acids. Indeed, both hepatic 7 $\alpha$ -hydroxylase mRNA levels and total fecal bile acids were elevated in the transgenic mice. Overall, these studies suggest that the overexpressing of the hepatic SR enhanced the flux of cholesterol secretion.

Based on our Northern blotting experiments in tissues from TgSR mice, SR mRNA expression was indeed confined predominantly to the liver. Hepatic fluorescent microscopy of the TgSR+/- mice injected with DiI-acetylated-LDL demonstrated SR activity in the sinusoidal endothelial cells, which normally express SR (Dresel H.A., Friedrich E., Via D.P., Sinn H., Ziegler R., Schettler G., supra., 1987; van Berkel T.J.C., Nagelkerke J.F., Kruijt J.K., supra., 1981; Dresel H.A., Friedrich E., Via D.P.,

-25-

Schettler G., Sinn H., supra., 1985; de Rijke Y.B.,  
van Berkel T.J.C., supra., 1994; Nagelkerke J.F.,  
Barto K.P., van Berkel T.J.C., supra., 1983;  
Pitas R.E., Boyles J., Mahley R.W., Montgomery B.D.,  
5 supra., 1985; Horiuchi S., Takata K., Maeda H.,  
Morino Y., supra., 1985; van Berkel T.J.C.,  
de Rijke Y.B., Kruijt J.K., supra., 1991; Esbach S.,  
Pieters M.N., Van der Boom J., et al., supra., 1993)  
and also in hepatocytes in which SR are normally almost  
10 undetectable (Nagelkerke J.F., Barto K.P.,  
van Berkel T.J.C., supra., 1983). Furthermore, our  
observation of a 2.5-fold enhanced clearance rate for  
ac-hLDL in the transgenic mice suggests a hepatic-  
directed clearance which affords a protective effect  
15 for atherosclerosis.

As has been suggested by the early studies from  
the laboratory of Brown and Goldstein (Brown M.S.,  
Goldstein J.L., supra., 1990), SR have been  
hypothesized to play a protective role in atherogenesis  
20 by removing modified lipoproteins. Indeed, apo B  
containing lipoproteins from rabbits fed high-  
cholesterol diets are more susceptible to  $\text{Cu}^{+2}$ -induced  
modification than LDL isolated from control rabbits  
in vitro (Nenseter M.S., Gudmundsen O., Malterud K.E.,  
25 Berg T., Drevon C., Biochim. Biophys. Acta., 1213:207-  
214 (1994)). Furthermore, studies of Palinski, et al.  
(Palinski W., Rosenfeld M.E., Ylä-Herttuala S., et al.,  
Proc. Natl. Acad. Sci. USA, 86:1372-1376 (1989)), have  
provided evidence for the in vivo oxidative  
30 modification of LDL in LDL-receptor-deficient rabbits.  
Furthermore, studies of Palinski, et al. (Palinski W.,  
Rosenfeld M.E., Ylä-Herttuala S., et al., supra., 1989;  
Palinski W., Ord V.A., Plump A.S., Breslow J.L.,  
Steinberg D., Witztum J.L., Arterioscler. Thromb.,  
35 14:605-616 (1994)), utilizing LDL-receptor deficient  
rabbits (Palinski W., Rosenfeld M.E., Ylä-Herttuala S.,

-26-

et al., supra., 1989) or apo E deficient-mice (Palinski W., Ord V.A., Plump A.S., Breslow J.L., Steinberg D., Witztum J.L., supra., 1994; Plump A.S., Smith J.D., Hayek T., Cell, 71:343-353 (1992)), have  
5 provided in vivo evidence for the oxidative modification of apo B containing lipoproteins by demonstrating the presence of high titers of autoantibodies to malondialdehyde-lysine, an epitope that presents on "modified" lipoproteins. Since  
10 significant quantities of "modified" apo B containing lipoproteins may also be formed in mice fed the HFHC diet, overexpression of the SR is likely responsible for their reduction, characterized by reduced amounts of apo B containing lipoprotein cholesterol. This  
15 hypothesized premise suggests that the SR expressed in vivo are exquisitely sensitive to slight modifications of lipoproteins, since these "modified" lipoproteins cannot be shown to accumulate in hypercholesterolemic plasmas. Furthermore, since  
20 "modified" lipoproteins are not observed in plasma it is also likely the capacity of SR is not exceeded. However, a competition between arterial subendothelial SR with those of liver likely exists. Thus, under conditions where hepatic SR expression is high,  
25 "modified" lipoproteins would be less likely to bind SR present in the aortic subendothelium. However, in certain pathophysiological or procedural-induced conditions (e.g., atherectomy, angioplasty), the arterial endothelium becomes compromised and the  
30 relative number and assess to subendothelial SR increases. If such a situation occurs in mammals, including humans, the modified lipoproteins would kinetically favor binding to the SRs expressed by cells in the subendothelium and could lead to enhanced  
35 arterial lipid deposition.

-27-

With respect to reduction of apo B containing lipoproteins we did not observe a gene dosage effect between the TgSR+/- and the TgSR+/+ mice. Possibly, sufficient SRs are produced in the heterozygous animals to efficiently remove all modified lipoproteins that form in these mice. The elevated rise in HDL was unexpected. The observation that HDL rose to a greater extent in the TgSR+/+ mice, or earlier in the TgSR+/- and TgSR+/+ mice suggested alterations in HDL metabolism. The explanation for this finding is not entirely clear and is cause for some speculation. Possibly, the catabolism of HDL is diminished in these mice. This may occur due to an increase removal of apo E with apo B containing particles, possibly reducing the apo E pool necessary for whole HDL particle clearance (Bisgaier C.L., Siebenkas M.V., Williams K.J., J. Biol. Chem., 264:862-866 (1989)). Alternatively, HDL production may be enhanced in these mice. This may occur due to increased expression of the SR. Possibly, elevated amounts of "modified" VLDL remnants are marginated within the liver due to the increased amounts of SR. The triglyceride and phospholipid of the trapped remnants, as well as circulating VLDL remnants and HDL, are hepatic lipase substrates (Jackson R.L., B. P. New York, 141-181 (1983)). Unlike other species liver-derived hepatic lipase in mice is not anchored to liver membrane glycosaminoglycan but freely circulates (Peterson J., Bengtsson-Olivercrona G., Olivecrona T., Biochim. Biophys. Acta., 878:65-70 (1986)). Therefore, increased levels of this enzyme may be sequestered near its site of synthesis due to the increased presence of bound "modified" VLDL remnant substrate to the SR receptors. Enhanced lipolysis of these modified "remnants" by hepatic lipase would lead to generation of redundant surface phospholipid that could

-28-

potentially elevate production of the HDL pool  
(Tall A.R., Small D.M., N. Engl. J. Med., 299:1232-1236  
(1978); Eisenberg S., Patsch J.R., Sparrow J.T., Gotto  
A.M. Jr., Olivecrona T., J. Biol. Chem., 254:12603-  
5 12608 (1979); Schaefer E.J., Wetzell M.G., Bengtsson G.,  
Scow R.O., Brewer H.B. Jr., Olivecrona T., J. Lipid  
Res., 23:1259-1273 (1982); Tam S.P., Breckenridge W.C.,  
J. Lipid Res., 24:1343-1357 (1983)). Since mice lack  
cholesteryl ester transfer protein (Agellon L.B.,  
10 Walsh A., Hayek T., et al., J. Biol. Chem., 260:10796-  
10801 (1990)), HDL triglyceride cannot be efficiently  
derived from VLDL and VLDL remnants by exchange with HDL  
cholesteryl esters (Tall A.R., J. Lipid Res., 34:1255-  
1274 (1993)), therefore, expansion of the particles'  
15 nonpolar core will be largely due to cholesteryl ester  
accumulation. Since HDL phospholipid surface are also  
substrate for hepatic lipase, and if this enzyme is  
largely sequestered in liver due to the increase  
presence of bound "modified" particles, a secondary  
20 effect would be reduced levels of circulating hepatic  
lipase. Therefore, an altered HDL catabolism might  
develop. Possibly, the phospholipid surface of these  
particles might not be subject to extensive lipolysis,  
which could allow these HDL to be better substrates for  
25 lecithin:cholesterol acyl transferase resulting in  
accumulation of core cholesteryl esters.

The SR gene can be introduced into cells by any of  
the many methods known for introducing DNA into cells,  
either transiently or stably ("Gene Therapeutics")  
30 Methods and Applications of Direct Gene Transfer,  
Wolff, J.A., ed., Birkhäuser, Boston, 1994;  
Kozarsky, K.F., McKinley, D.R., Austin, L.L.,  
Raper, S.E., Stratford-Perricaudet, L.D., Wilson, J.M.,  
J. Biol. Chem 269:13695-13702 (1994); Henry, J. and  
35 Gerard, R.D., Proc. Natl. Acad. Sci. USA 90:2812-2816  
(1993); Archer, J.S., Hennan, W.S., Gould, M.N.,

-29-

Bremel, R.D., Proc. Natl. Acad. Sci. USA 91:6840-6844 (1994); Wolff, J.A., Malone, R.W., Williams, P., Chang, W., Acsadi G., Jani, A., Felgner, P.L., Science 247:1465-1468 (1990); Wolff, J.A., Williams, P.,  
5 Ascadi, G., Jiao, S., Chong, W., Biotechniques 11:474-485 (1991); Barr, E. and Leiden, J.M., TCM 4:57-62 (1994); Kozarsky, K., Grossman, M., Wilson, J.M., Somatic Cell and Molecular Genetics 19:449-458 (1993); Wu, C.H., Wilson, J.M., Wu, G.Y.,  
10 J. Biol. Chem. 264:16985-16987 (1989); Ishibashi, S., Brown, M.S., Goldstein, J.L., Gerard, R.D., Hammer, R.E., Herz, J., J. Clin. Invest. 92:883-893 (1993); Liu, T.J., Kay, M.A., Darlington, G.J., Woo, S.L., Somatic Cell and Molecular Genetics 18:89-96  
15 (1992); Kay, M.A., Li, Q., Liu, T.J., Leland, F., Toman, C., Finegold, M., Woo, S.L., Hum. Gene Ther. 3:641-647 (1992); Kay, M.A., Ponder, K.P., Woo, S.L., Breast Cancer Res. Treat. 21:83-93 (1992); Chen, S.H., Shine, H.D., Goodman, J.C., Grossman, R.G., Woo, S.L.,  
20 Proc. Natl. Acad. Sci USA 91:3054-3057 (1994); Kolodka, T.M., Finegold, M., Woo, S.L., Somatic Cell and Molecular Genetics 19:491-497 (1993)). The methods for introducing DNA into cells include calcium phosphate coprecipitation, cationic liposomes,  
25 electroporation, receptor mediated endocytosis, particle-mediated gene transfer, attachment to synthetic peptides, or for some cell types, naked DNA can be used. The SR genes can also be introduced by any of the well-known viral vectors, including  
30 retroviruses, adenovirus, adeno-associated virus, and herpes viruses. Thus, the SR gene of the present invention can be introduced into cells by conventional gene transfer technology known to those skilled in the art.

35 The use of the SR to attenuate hypercholesterolemia and its pathological sequelae in the

-30-

form of gene therapy proceeds as follows. The SR minigene construct is prepared using either a viral or nonviral method of delivery. The formulation could be, for example, using cationic liposomes (Philip B., et al., J. Biol. Chem., 268:16087-16090 (1993)) where 10 µg to 10 mg of a vector expressing the scavenger receptor is delivered. For in vivo administration, it will usually be preferred to use a vector that will direct tissue-specific gene expression to the liver. The resulting preparation is infused intravenously into candidate patients, and the efficacy of treatment is monitored by measuring the patient's plasma cholesterol and its distribution among lipoproteins. Alternatively, the treatment is carried out ex vivo. A portion of the patient's liver is surgically removed. Liver parenchymal cells are isolated by standard techniques and placed in tissue culture. The liver cells are then transfected with the SR gene by standard techniques, placed in culture for several days, and tested for the cell surface expression of the SR. The resulting cell preparation is then reinfused into the patient wherein the liver cells take up residence in the liver and express the SR. Efficacy of treatment is monitored by measuring plasma total cholesterol and its distribution among lipoproteins. Optimal treatment of a patient receiving SR gene therapy will often involve coadministration with an ACAT inhibitor; a HMG-CoA reductase inhibitor, a bile acid sequestrant, or a lipid regulator.

Examples of ACAT inhibitors include DL-melinamide disclosed in British Patent 1,123,004 and Japan. J. Pharmacol., 42:517-523 (1986); 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide disclosed in U.S. Patent 4,716,175; N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-(4-dimethylaminophenyl)cyclopentyl]methyl]urea disclosed in U.S. Patent 5,015,644; 2,6-bis(1-methyl-



-31-

ethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-  
sulfamate disclosed in copending U.S. Patent  
Application Serial Number 08/233,932 filed April 13,  
1994; and the like. U.S. Patents 4,716,175 and  
5,015,644 and U.S. Patent Application Serial  
Number 08/233,932 and British Patent 1,123,004 and  
Japan. J. Pharmacol, 42:517-523 (1986) are hereby  
incorporated by reference.

Examples of HMG-CoA reductase inhibitors include  
lovastatin disclosed in U.S. Patent 4,231,938;  
pravastatin disclosed in U.S. Patent 4,346,227;  
simvastatin disclosed in U.S. Patent 4,444,784;  
fluvastatin disclosed in U.S. Patent 4,739,073;  
atorvastatin disclosed in U.S. Patents 4,681,893 and  
5,273,995; and the like. U.S. Patents 4,231,938,  
4,346,227, 4,444,784, 4,681,893, 5,273,995, and  
4,739,073 are hereby incorporated by reference.

Examples of bile acid sequestrants include  
colestipol disclosed in U.S. Patents 3,692,895 and  
3,803,237; cholestyramine disclosed in U.S. Patent  
3,383,281 and R. Casdorph in Lipid Pharmacology  
2:222-256, Paoletti C, Glueck J., eds. Academic Press,  
NY 1976; and the like. U.S. Patents 3,692,895,  
3,803,237, and 3,383,281 and R. Casdorph, supra, are  
hereby incorporated by reference.

Examples of lipid regulators include gemfibrozil  
described in U.S. Patent 3,674,836; bezafibrate  
disclosed in U.S. Patent 3,781,328; clofibrate  
disclosed in U.S. Patent 3,262,850; fenofibrate  
disclosed in U.S. Patent 4,058,552; niacin disclosed in  
McElvain, et al., Org. Syn., 4:49 (1925); and the like.  
U.S. Patents 3,674,836, 3,781,328, 3,262,850, and  
4,058,552 and McElvain, et al., Org. Syn., 4:49 (1925)  
are hereby incorporated by reference.

35

-32-

The following nonlimiting examples illustrate the inventor's preferred methods for preparing a SR gene of the present invention.

## EXAMPLE 1

5 Bovine SR Minigene Preparation

A partial SR Type I cDNA clone was isolated from a bovine lung  $\lambda$ gt10 cDNA library (Clontech Laboratories, Inc, Palo Alto, California) using three  
10 oligonucleotides that were selected based on the published sequence (Kodama T., Freeman M., Rohrer L., Zabrecky J., Matsudaira P., Kreiger M., Nature,  
343:531-535 (1990)). This cDNA fragment, 1.8 kb in length, was subcloned into pGEM 3Zf (-) (Promega Corp, Madison, Wisconsin). The missing 0.3 kb of the 5' end  
15 of the partial cDNA clone was synthesized by coupled reverse transcriptase and polymerase chain reaction (PCR) (Mullis K.B., Faloona F.A., Methods in Enzymology, 155:335-350 (1987); Saiki R.K., Gelfand D.H., Stoffel S., Science, 239:487-491 (1988))  
20 using bovine lung mRNA (Clontech Laboratories, Inc) as a template and the specific 5' (5'-GGGCGTCCGGAT-TTGGAGATATATCTGCA-3') and 3' (5'-GCCGATCCGAAGTATGGC-ACGTGGGATGACTTTCC-3') primers. This cDNA generated fragment was then ligated into the pGEM 3Zf (-) clone  
25 (Promega Corp, Madison, Wisconsin) that contained 1.8 kb of bovine SR between BamHI in the plasmid polylinker site and the SR sequence internal AccIII restriction site. The full length bovine SR cDNA was verified (Kodama T., Freeman M., Rohrer L.,  
30 Zabrecky J., Matsudaira P., Kreiger M., supra., 1990) by nucleotide sequencing using the dideoxy-chain termination method (Sanger F., Nicklen S., Coulson A.R., Proc. Natl. Acad. Sci. USA, 74:5463-5467 (1977)). To construct the bovine SR minigene  
35 approximately 3 kb of the mouse transferrin promoter (Idzerda R.L., Behringer R.R., Theisen M.,

-33-

Huggenvik J.I., McKnight G.S., Brinster R.L., Mol. Cell. Biol., 2:5154-5162 (1989)) was ligated to the 5' end of the bovine SR cDNA. The mouse transferrin promoter contained an artificially introduced BamHI restriction site (Idzerda R.L., Behringer R.R., Theisen M., Huggenvik J.I., McKnight G.S., Brinster R.L., supra., 1989) at the 3' end which was convenient for ligation to the bovine SR clone. The resulting construct contained 5 bp of the 5' untranslated region of the bovine SR upstream of the ATG start site. Inclusion of this short 5 bp untranslated region in the construct appears to be necessary for efficient translation (i.e., "first AUG rule") (Kozak M., supra., 1986; Kozak M., supra., 1989). At the 3' end of the promoter-bovine SR construct, 0.65 kb of the human growth hormone gene sequence containing the stop signal was ligated at a Asp700/SmaI fusion site (Figure 1). The total size of the minigene construct was 5.2 kb and was isolated by cutting with EcoRI (5' end) and NotI (3' end), purified with Qiaex (Qiagen Inc, Chatsworth, California) and utilized for production of transgenic mice.

## EXAMPLE 2

25 Production of Bovine SR Transgenic Mice

Fertilized one-cell embryos were isolated from superovulated C57BL/6J x FVB mice (Jackson Laboratories). To create transgenic mice, approximately 1000 male pronuclei of the fertilized embryos were microinjected with the purified 5.2 kb minigene construct described above at a DNA concentration of 3 ng/ $\mu$ L (Brinster R.L., Palmiter R.D., The Harvey Lectures, Series 80:1-38 (1980); Hogan B., Costantini F., Lacy E., Cold Spring Harbor Laboratory. New York, 1986) and reimplanted into ICR pseudo-pregnant mice. Forty-five potential founders were

-34-

screened by Southern blotting and PCR (see below). Of these, three mice were positive and, therefore, breed to C57BL/6J mates. Of the three founders, only one female mouse (Mouse 1876) incorporated the transgene in the germline and passed it on to offspring; the other two potential founders were chimerics. A heterozygous line (TgSR+/-) was established by breeding Mouse 1876 to nontransgenic C57BL/6J mice. Homozygous mice (TgSR+/+) were obtained by crossing TgSR+/- . Both TgSR+/- appeared healthy and thrive for at least 2 years and the TgSR+/+ have been healthy since their creation (approximately 0.5 years).

Bovine SR minigene transmission in founder and offspring generations was confirmed by both Southern blot analysis (Southern E.M., J. Mol. Biol., 98:503-517 (1975)) and PCR. For Southern blot analysis, genomic DNA (10 µg) was digested with restriction enzymes EcoRI and BamHI or BamHI alone. The samples were electrophoresed in a 1% agarose gel and blotted onto Zetaprobe membranes (Bio-Rad, Laboratories, Hercules, California). Blots were prehybridized for 5 to 6 hours at 42°C, and then hybridized overnight to a 0.7 kb fragment (see Figure 1) that was random primed (Boeringer Mannheim, Indianapolis, Indiana) using <sup>32</sup>P-dCTP (Amersham Corp, Arlington Heights, Illinois). By PCR analysis, using the bovine specific primers 5'-CCTCCATCCAGGAACATGAG-3' and 5'-CCTTTTCTGTGGA-TAAAATTC-3', a 1 kb cDNA fragment could be amplified from transgenic mice but not from nontransgenic littermates.

Southern blot analysis was used to estimate transgene copy number. TgSR+/- genomic DNA hybridization intensities were compared to standards comprised of control mouse genomic DNA containing variable amounts of the bovine SR minigene DNA.

-35-

## EXAMPLE 3

RNA Analysis

Tissue specific expression of bovine SR, mouse 7 $\alpha$ -hydroxylase and mouse actin (Ambion, Inc, Austin, TX) mRNA were determined by Northern blot analysis. Total RNA was isolated from liver, spleen, lung, brain, heart, kidney, small intestine, large intestine, ovary, adipose, and muscle from control and transgenic mice with RNazol (Biotecx Laboratories, Inc, Houston, Texas) according to instructions supplied with reagent. Quantitative and qualitative assessment of total RNA were determined spectrophotometrically and on 1% analytical agarose gels, respectively.

Before performing Northern blot analysis total liver RNA (5  $\mu$ g) from TgSR+/- and nontransgenic littermates were used for reverse transcriptase reactions utilizing the upstream specific bovine SR primer (5'-CCTTTTCTGTGGATAAAATTC-3') and a first strand cDNA synthesis kit (Superscript, BRL). A control reaction without the reverse transcriptase enzyme (Seikagaku America, Inc) was performed. The reaction proceeded for 15 minutes at 37°C, and then at 42°C for an additional 30 minutes. The reverse transcriptase product, was subject to PCR amplification in the presence of the down stream primer (5'-CCTCCATCCA-GGAACATGAG-3') and a PCR amplification kit (Perkin-Elmer). The product was analyzed on a 1% agarose gel.

For Northern analysis, samples (10  $\mu$ g total RNA) were heated at 70°C for 10 minutes in loading buffer (DEPC water, 1  $\times$  MOPS, 6.6% formaldehyde, 50% formamide, 5% glycerol, bromophenol blue), and then separated by 6.3% formaldehyde-1% agarose gel electrophoresis. RNA was transferred onto Zetaprobe membranes in 10  $\times$  SSC buffer and hybridized to the random primed 0.7 kb <sup>32</sup>P-bovine SR cDNA probe described

-36-

above (Figure 1) at 65°C. Blots were first washed with 0.1 × SSC/0.1% SDS at room temperature for 10 minutes, and then at 50°C for additional 10 minutes. Blots were exposed to X-Omat AR film (Eastman Kodak, Rochester, New York). In a separate northern blot experiment it was shown that the <sup>32</sup>P-bovine SR cDNA probe does not recognize the endogenous mouse SR; similarly, a 0.2 kb <sup>32</sup>P-mouse SR cDNA probe was shown to be specific for the mouse SR. To estimate hepatic bovine SR relative abundance to that of the endogenous mouse SR mRNA, duplicate northern blots of hepatic mRNA from control and TgSR+/- mice were hybridized to either the mouse or bovine specific SR cDNA probe and processed in a similar fashion as above.

Northern blot analysis was also used to quantitate endogenous hepatic 7α-hydroxylase and actin mRNA levels in control and TgSR+/- mice fed a HFHC diet. Total liver mRNA (10 µg/lane) was electrophoresed on a formaldehyde gel and then transferred in 20 × SSC buffer to a nitrocellulose membrane (Schleicher & Schuell, Inc Keene, New Hampshire). The membrane was baked for 1.5 hours at 80°C, prehybridized, and then hybridized at 62°C using formamide conditions. Both 0.3 kb mouse 7α-hydroxylase and mouse actin riboprobes were generated using a run off kit (Riboprobe Gemini II Core System, Promega) and <sup>32</sup>P-CTP (Amersham). The membranes were subject to three 10-minute 2 × SSC/0.2% SDS washes, first at 40°C, then at 50°C, and then at 62°C (7α-hydroxylase) or 50°C (actin). For 7α-hydroxylase two additional washes continued at 65°C in 0.1 × SSC/0.2% SDS for 10 minutes and then for 20 minutes. For actin, one additional wash continued at 50°C in 0.1 × SSC/0.2% SDS for 10 minutes. Image analysis and quantitation of Northern bands were determined on a Molecular Dynamics 400E Phosphorimager (Molecular Dynamics, Sunnyvale, California).

-37-

## EXAMPLE 4

Protein Quantification

For different portions of these studies, protein was determined with either the BCA protein assay reagent (PIERCE, Rockford, Illinois), by the method of Bradford (Bradford M.M., Anal. Biochem., 72:248-254 (1976)) or Lowry et al. (Lowry O.H., Rosebrough N.J., Farr A.C., Randall R.J., J. Biol. Chem., 193:265-275 (1951)). In all cases bovine serum albumin was used as a standard.

## EXAMPLE 5

Western Blot Analysis

Liver membranes were isolated from control and TgSR+/- mice according to the method of Via, et al. (Via D.P., Dresel H.A., Gotto A.M. Jr., Methods in Enzymology, 129:216-226 (1986)). Briefly, livers were homogenized in 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 10 U/mL aprotinin, pH 8.0 (4 mL/g tissue), and spun by at 1500 g for 10 minutes at 4°C to remove cellular debris. Supernatants were centrifuged at 100,000 g (40,000 rpm in a Beckman Ti60 rotor) for 1 hour at 4°C, and membrane pellets were resuspended in ice-cold 40 mM octyl  $\beta$ -glucopyranoside in 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 10 U/mL aprotinin, pH 8.0. Nonreduced membrane proteins were electrophoresed on 7.5% SDS polyacrylamide gels and transferred electrophoretically (100 V for 1.5 hours at room temperature) to nitrocellulose membranes. Membranes were blocked with 5% nonfat dried milk (blotto) in 50 mM Tris-HCl, 150 mM NaCl, pH 8.0 and then incubated with guinea pig anti-bovine SR IgG (DeJager S., Mietus-Synder M., Pitas R.E., Arterioscler. Thromb., 13:371-378 (1993); Pitas R.E., Frieria A., McGuire J., DeJager S.,

-38-

Arterioscler. Thromb., 12:1235-1244 (1992)). Following incubation with goat anti-rabbit IgG (which cross reacts with guinea pig IgG) conjugated to alkaline phosphatase, the bovine SR-antibody complexes were visualized with an ECL detection system (Amersham).

## EXAMPLE 6

LDL Isolation and Modifications

Human LDL (hLDL) was isolated by sequential ultracentrifugation between the density intervals of 1.019 to 1.050 g/mL (Havel R.J., Eder H.A., Bragdon J.H., J. Clin. Invest., 34:1345-1353 (1955)). hLDL was acetylated with acetic anhydride (ac-hLDL) (Goldstein J.L., Ho Y.K., Basu S.K., Brown M.S., supra., 1979) and used in fluorescence studies (see below). Ac-hLDL was radiolabeled with  $^{125}\text{I}$  by the iodine monochloride method of MacFarlane (McFarlane A.S., Nature, 182:53 (1958)) and was used for kinetic studies (see below).

## EXAMPLE 7

Fluorescence Histochemistry

Ac-hLDL was labeled with DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate) according to the method of Voyta, et al. (Voyta J.C., Via D.P., Butterfield C.E., Zetter B.R., J. Cell Biol., 99:2034-2040 (1984)). Control and TgSR+/- mice were tail vein injected with DiI ac-hLDL (320  $\mu\text{g}$ , 1.6  $\mu\text{g}/\mu\text{L}$ ). After 10 minutes, mice were sacrificed and liver tissue was rinsed in PBS and cut into pieces for embedding in OCT (Baxter) on dry ice. Cryostat sections (3-5  $\mu\text{m}$ ) were placed on polylysine-coated slides and analyzed by fluorescence microscopy using a rhodamine filter set.



-39-

## EXAMPLE 8

In Vivo Clearance of Acetylated LDL

The kinetics of  $^{125}\text{I}$ -ac-hLDL clearance in five TgSR $\pm$  and five control mice was determined. Mice were tail vein injected with  $^{125}\text{I}$ -ac-hLDL (1.6 mg protein, 0.2 mL). Orbitalsinus blood samples (10  $\mu\text{L}$ ) were collected periodically up to 8 minutes in heparinized microcapillary tubes. Radioactivity data are expressed as percent of the first 20-second time point. To control for nonscavenger receptor mediated  $^{125}\text{I}$ -ac-hLDL clearance, three TgSR $\pm$  and three control mice were coinjected with 0.1 mL of  $^{125}\text{I}$ -ac-hLDL preparation plus 0.1 mL Fucoidan (10 mg/mL) (Brown M.S., Goldstein J.L., Krieger M., Ho Y.K., Anderson R.G.W., supra., 1979).

## EXAMPLE 9

Food Consumption Studies

Five TgSR $\pm$  and five control mice were maintained on a high-fat, high-cholesterol (HFHC) diet (Diet D12336, Research Diets, Inc, New Brunswick, New Jersey) for 3 weeks in individual metabolic cages. The HFHC diet was similar to the atherogenic diet used by Paigen, et al. (Paigen B., Morrow A., Bradon C., Mitchell D., Holmes P., Atherosclerosis, 57:65-73 (1985)), and contained 1.25% cholesterol, 16% fat (5% soy bean oil, 7.5% cocoa butter, and 3.5% coconut oil), and 0.5% cholic acid. The selected animals had an average body weight of 22 to 25 g and were 2 months old. Each group consisted of three males and two females. The weekly amounts of diet consumed by each animal was calculated at Days 7, 14, and 21.

-40-

## EXAMPLE 10

Feeding Study

Five TgSR+/-, four TgSR+/+, and five control mice maintained on chow were fasted for 7 to 8 hours prior to obtaining 0.3 mL blood from the tail while under Metofane (Pro-Vet) anesthesia. Mice were then put on the HFHC diet for 3 weeks. Mice were bleed weekly following a 7- to 8-hour fast.

## EXAMPLE 11

Lipoprotein and Lipid Analysis

Lipoprotein total cholesterol distribution in 10  $\mu$ L plasma samples was determined continuously on-line in the postcolumn eluant following Superose 6 (Pharmacia Biotech Inc, Piscataway, New Jersey) high performance gel-filtration chromatography essentially as described (Kieft K.A., Bocan T.M.A., Krause B.R., J. Lipid Res., 32:859-866 (1991); Aalto-Setälä K., Bisgaier C.L., Ho A., et al., J. Clin. Invest., 93:1776-1786 (1994)) except that we used a Rainin HPLC and Dynamax Compare software (Rainin Instrument Co, Inc, Woburn, Massachusetts) for instrumentation and data reduction, respectively. Total plasma triglycerides were determined enzymatically with a commercially available kit (Trigli-cinet 2 kit, Sclavo Inc, Wayne, New Jersey). Total plasma cholesterol were determined enzymatically according to the method of Allain, et al. (Allain C.C., Poon L.S., Chan C.S.G., Richmond W., Fu P.C., Clin. Chem., 20:470-475 (1974)).

## EXAMPLE 12

Analysis of Hepatic Lipids

Major hepatic lipid classes were determined in five TgSR+/- and four control mice that were on the HFHC diet for 25 days. Livers (0.5 g) were homogenized in a total volume of 5 mL phosphate-buffered saline.

-41-

Aliquots were removed for protein determination (Lowry O.H., Rosebrough N.J., Farr A.C., Randall R.J., supra., 1951) and extraction of liver lipids. Homogenized liver (1.0 mL) was extracted with 6 mL ethyl acetate/acetone (2/1:v/v) containing 0.01% butylated hydroxytoluene and a 4-hydroxy-cholesterol (1 mg) internal standard in teflon-lined screw-cap 20-mL glass tubes according to the method of Slayback, et al. (Slayback J.R.B., Cheung L.W.Y., Geyer R.P., Anal. Biochem., 83:372-384 (1977)). Samples were vigorously mixed for 10 minutes and extraction continued overnight. Following addition of 2 mL water, and 5 minutes low speed centrifugation (500 rpm), the upper phase containing both polar and nonpolar lipids was removed and evaporated to dryness under nitrogen. Residual solvent was removed by lyophilization. Dried lipids were solubilized in 200  $\mu$ L of iso-octane/tetrahydrofuran (97/3:v/v) and 5  $\mu$ L were injected onto a 4.6  $\times$  100 mm silica column equilibrated with iso-octane/tetrahydrofuran (97/3:v/v) on a Spectra Physics HPLC by a modification of the method of Christie (Christie W.W., J. Lipid Res., 26:507-512 (1985)). Postcolumn eluant was detected in a evaporative light scattering detector (Varex, Model ELSD IIA). Authentic lipid standards were utilized to calibrate the detector response for the various major lipid classes.

## EXAMPLE 13

Determination of Fecal Bile Acids

Five TgSR+/- and five control mice were maintained on chow diets in individual metabolic cages for 1 week, followed by a high-fat, high-cholesterol diet for 3 weeks. Total feces from each mouse was collected at the end of each week and stored at -20°C. Total fecal bile acids was determined by the fluorescence method of Beher, et al. (Beher W.T., Strandnieks S., Lin G.J.,

-42-

Sanfield J., Steroids, 38:281-295 (1981)). Briefly, feces was homogenized in three volumes of water. An aliquot of the fecal homogenate (1 g) was mixed with 7 mL of ethanol and heated to 70°C for 30 minutes. The mixture was then filtered through a pleated filter and washed once with 6 mL of preheated ethanol. A 4-mL aliquot from each sample was dried under nitrogen and then dissolved in 2 mL of 3 M NaOH and heated at 100°C for 2 hours. Samples (10  $\mu$ L), 2.4 mL of tris buffer pH 9 and 0.5 mL of reagent (2 mg resazurin, 100 mg  $\beta$ -NAD, 6.4 units of hydroxysteroid oxidoreductase and 37 units of diaphorase in 100 mL of 0.05 M pH 7.4 phosphate buffer containing 19.1 mg sucrose, 0.1  $\mu$ g dithioerythritol, 7.5 mg EDTA, and 50 mg bovine serum albumin) were incubated at room temperature for 1.5 hours. Samples were excited at 565 nm and emission fluorescence determined at 580 nm in a fluorescence spectrophotometer model LS-3 (Perkin-Elmer, Oakbrook, IL). Standards of cholic acid were used to calibrate the assay.

## EXAMPLE 14

Cholesterol Absorption

Cholesterol absorption was determined in three control and five TgSR $\pm$  mice by determination of the differential absorption of cholesterol and  $\beta$ -sitosterol on a HFHC diet. Briefly, mice individually housed in metabolic cages were maintained ad libitum on a chow diet prior to intragastric bolus administration of  $^3$ H-cholesterol (1.5  $\mu$ Ci) plus  $^{14}$ C- $\beta$ -sitosterol (0.1  $\mu$ Ci) in 100  $\mu$ L sunflower seed oil. Mice were then allowed ad libitum access to the HFHC diet for 4 days. An aliquot of the oral dose and a homogenate of the feces collected over the 4 days were extracted with ethyl acetate/acetone (2/1:v/v) and processed in a similar fashion as described above for extraction of

-43-

hepatic lipids. Radioactivity in an aliquot of the lipid phase was determined by liquid scintillation counting. The ratio of  $^3\text{H}$  to  $^{14}\text{C}$  in the extracts were determined and used to estimate percent cholesterol  
5 absorption by the following formula:

$$\text{Percent Cholesterol Absorption} = 100 \times \frac{((^3\text{H}/^{14}\text{C in Oral Dose}) - (^3\text{H}/^{14}\text{C in Feces}))}{(^3\text{H}/^{14}\text{C in Oral Dose})}$$

-44-

## CLAIMS

1. A method for introducing a scavenger receptor gene  
into the liver of a mammal to make said mammal  
5 resistant to atherosclerosis, comprising  
introducing the DNA into a mammal by a process of  
delivery selected from the group consisting of:  
(a) use of calcium phosphate coprecipitation;  
(b) in a complex of cationic liposomes;  
10 (c) electroporation;  
(d) receptor-mediated endocytosis;  
(e) naked DNA;  
(f) transduction by a viral vector;  
(g) particle-mediated gene transfer; and  
15 (h) synthetic peptides.
2. The method of Claim 1 wherein the mammal is a  
human.
3. A method for introducing a scavenger receptor gene  
into a mammal to make said mammal resistant to  
atherosclerosis comprising inserting said  
scavenger receptor gene into a vector and  
expressing the scavenger receptor in the liver of  
5 said mammal.
4. The method of Claim 3 wherein the mammal is a  
human.
5. The ectopic expression of a scavenger receptor in  
the liver of a mammal for the reduction of apo B  
containing lipoproteins, elevation of high-density  
lipoprotein cholesterol, and prevention of  
atherosclerosis.

-45-

6. The ectopic expression of a scavenger receptor according to Claim 5 wherein the mammal is a human.
7. The ectopic expression of a scavenger receptor according to Claim 5 wherein expression is transient expression in the liver.
8. The ectopic expression of a scavenger receptor according to Claim 5 wherein expression is stable expression in the liver.
9. A method of treating atherosclerosis; hyperbetalipoproteinemia; hypercholesterolemia; hypertriglyceridemia; hypoalphalipoproteinemia; vascular complications of diabetes; transplant, atherectomy, and angioplastic restenosis in a  
5 patient comprising administering to the liver of said patient a therapeutically effective amount of a scavenger receptor gene.
10. A method of treating atherosclerosis; hyperbetalipoproteinemia; hypercholesterolemia; hypertriglyceridemia; hypoalphalipoproteinemia; vascular complications of diabetes; transplant, atherectomy, and angioplastic restenosis in a  
5 patient comprising administering to the liver of said patient a therapeutically effective amount of a scavenger receptor gene in combination with one or more agents selected from the group consisting of:  
10 (a) ACAT inhibitor;  
(b) HMG-CoA reductase inhibitor;  
(c) lipid regulator; and  
(d) bile acid sequestrant.


-46-

11. A pharmaceutical delivery method adapted for hepatic administration to a patient in an effective amount of an agent for treating atherosclerosis; hyperbetalipoproteinemia; hypertriglyceridemia; hypercholesterolemia; hypoalphalipoproteinemia; vascular complications of diabetes; transplant, atherectomy, and angioplastic restenosis comprising a scavenger receptor gene and a suitable viral or nonviral delivery system.
12. A pharmaceutical delivery method according to Claim 11 adapted for ex vivo or in vivo delivery.
13. A pharmaceutical delivery method according to Claim 11 directed to therapeutic or prophylactic administration.



1/18

FIG. 1



2/18

FIG. 2A




FIG. 2B





FIG. 3



4/18



FIG. 4A

Control  
250x  
(3-5  $\mu$ M slices )

5/18



FIG. 4B

Transgenic  
1000x  
(3-5  $\mu$ M slices )

6/18

FIG. 5




FIG. 6A




FIG. 6B






FIG. 6C






FIG. 6D




11/18

FIG. 7A




12/18

FIG. 7B




13/18

FIG. 7C




14/18

FIG. 8A



15/18

FIG. 8B



16/18

FIG. 9






FIG. 10A

~ 4kb →






FIG. 10B

~ 2kb →



18/18

FIG. 10C



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 95/11595

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/705 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,94 10322 (UNIV TEXAS ;HERZ JOACHIM (US); GERARD ROBERT D (US)) 11 May 1994 see the whole document ---	1-8, 11-13
Y	WO,A,92 12242 (WHITEHEAD BIOMEDICAL INST ;HUGHES HOWARD MED CENTER (US)) 23 July 1992 see page 46, line 34 - page 47, line 24; claims 1-19 ---	1-8, 11-13
Y	DATABASE WPI Section Ch, Week 9207 Derwent Publications Ltd., London, GB; Class B04, AN 92-051436 & JP,A,03 290 184 ( CHUGAI PHARMACEUTICAL KK) , 19 December 1991 see abstract --- -/--	1-8, 11-13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

29 February 1996

Date of mailing of the international search report

19.03.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Gurdjian, D

## INTERNATIONAL SEARCH REPORT

Internatic Application No

PCT/US 95/11595

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE WPI  Section Ch, Week 9335  Derwent Publications Ltd., London, GB;  Class B04, AN 93-277488  &amp; JP,A,05 192 179 ( CHUGAI PHARM CO LTD) ,  3 August 1993  see abstract</p> <p>---</p>	1-8, 11-13
A	<p>NATURE ,  vol. 343, 1990  pages 531-535,  T.KODAMA ET AL. 'Type I macrophage  scavenger receptor contains alpha-helical  and collagen-like coiled coils'  cited in the application  see the whole document</p> <p>---</p>	1-8, 11-13
A	<p>NATURE ,  vol. 343, 1990  pages 570-572,  L.ROHRER ET AL. 'Coiled-coil fibrous  domains mediate ligand binding by  macrophage scavenger receptor type II'  cited in the application  see the whole document</p> <p>---</p>	1-8, 11-13
A	<p>WO,A,89 07136 (WHITEHEAD BIOMEDICAL INST  ;HUGHES HOWARD MED INST (US)) 10 August  1989  see claims 1-27</p> <p>---</p>	1-8, 11-13
A	<p>JOURNAL OF THE AMERICAN COLLEGE OF  CARDIOLOGY,  vol. 23, no. 6, May 1994  pages 1278-1288,  EPSTEIN SE ET AL 'THE BASIS OF MOLECULAR  STRATEGIES FOR TREATING CORONARY  RESTENOSIS AFTER ANGIOPLASTY'  see the whole document</p> <p>-----</p>	11

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/ 11595

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-13  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 1-13 refer, at least partially as far as it concerns in vivo method, to a method of treatment of the human body, the search has been carried out and has been based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

II. Information on patent family members

International Application No

PCT/US 95/11595

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9410322	11-05-94	AU-B- 5457294	24-05-94
WO-A-9212242	23-07-92	AU-B- 9179591	17-08-92
		CA-A- 2076848	27-06-92
		EP-A- 0517909	16-12-92
WO-A-8907136	10-08-89	EP-A- 0400047	05-12-90
		JP-T- 3503718	22-08-91